TORC - resTORbio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.00
-0.28 (-3.85%)
At close: 4:00PM EDT

7.00 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close7.28
Open7.30
Bid6.99 x 800
Ask7.01 x 1200
Day's Range6.98 - 7.68
52 Week Range6.21 - 14.05
Volume130,678
Avg. Volume144,921
Market Cap253.552M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.44
Earnings DateAug 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.33
Trade prices are not sourced from all markets
  • GlobeNewswire

    AMAG Pharmaceuticals Announces Settlement Agreement with Caligan Partners LP

    AMAG Pharmaceuticals, Inc. (AMAG) (“AMAG”) today announced that it has entered into a settlement agreement with Caligan Partners LP (“Caligan”). As part of this agreement, the Board of Directors has appointed Paul Fonteyne, former Chief Executive Officer of Boehringer Ingelheim USA, and David Johnson, Partner and co-Founder of Caligan, to the AMAG Board, effective immediately.

  • GlobeNewswire

    resTORbio Presents New Findings on RTB101 During Late-Breaking Session at IDWeek 2019

    BOSTON, Oct. 02, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, will present new data today about RTB101, the company’s investigational oral, selective, and potent TORC1 inhibitor, during the Infectious Disease Society of America (IDSA) IDWeek™ 2019 conference. RTB101 inhibits the TORC1 pathway and has been observed to upregulate innate antiviral immunity and reduce the incidence of illnesses associated with respiratory tract infections (RTIs) in older adults.

  • GlobeNewswire

    resTORbio to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    BOSTON, Sept. 25, 2019 -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent.

  • GlobeNewswire

    resTORbio to Present Findings on Investigational TORC1 Inhibitor RTB101 in Late-Breaking Session at IDWeek™ 2019

    BOSTON, Sept. 23, 2019 -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to.

  • GlobeNewswire

    resTORbio Reports Second Quarter 2019 Financial Results and Corporate Update

    – Quarter highlighted by initiation and early completion of enrollment of Phase 3 PROTECTOR 1 trial; topline data expected by early first quarter of 2020 – BOSTON, Aug..

  • GlobeNewswire

    resTORbio to Present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019

    BOSTON, Aug. 07, 2019 -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent.

  • GlobeNewswire

    resTORbio Announces Early Completion of Enrollment of Phase 3 PROTECTOR 1 Trial with RTB101 in Clinically Symptomatic Respiratory Illness

    BOSTON, July 23, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (TORC) today announced that it has completed patient enrollment of the Phase 3 PROTECTOR 1 trial, ahead of previously announced clinical timelines, with 1,024 patients randomized. PROTECTOR 1 is the first of two global Phase 3 clinical trials evaluating the potential of RTB101 to improve the immune function of patients aged 65 and older and thereby decrease the incidence of illness associated with respiratory tract infections (RTIs). “We are very pleased with the rapid pace of enrollment of PROTECTOR 1, which now puts us on a timeline to potentially announce topline data from this Phase 3 study by early first quarter of 2020,” said Chen Schor, co-founder, president and chief executive officer of resTORbio.

  • resTORbio, Inc.'s Shares March Higher, Can It Continue?
    Zacks

    resTORbio, Inc.'s Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in resTORbio.

  • Introducing resTORbio (NASDAQ:TORC), The Stock That Dropped 20% In The Last Year
    Simply Wall St.

    Introducing resTORbio (NASDAQ:TORC), The Stock That Dropped 20% In The Last Year

    Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you...

  • GlobeNewswire

    resTORbio Presents Additional Phase 2b Data at the American Thoracic Society International Conference for RTB101 as a Potential Immunotherapy to Reduce the Incidence of Respiratory Tract Infections in Patients 65 Years of Age and Older with Asthma

    BOSTON, May 20, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (TORC) today announced additional data from the Phase 2b clinical trial of RTB101, an orally administered, small molecule, potent inhibitor of target of rapamycin complex 1 (TORC1). RTB101 was well-tolerated and was observed to reduce the incidence of respiratory tract infections (RTIs) in patients 65 years of age and older at high risk of morbidity and mortality due to RTIs, including those with asthma.

  • GlobeNewswire

    resTORbio Reports First Quarter 2019 Financial Results and Corporate Update

    Initiated first Phase 3 trial, PROTECTOR 1, of RTB101 in clinically symptomatic respiratory illness; top-line data from two pivotal Phase 3 trials expected in mid-2020.

  • GlobeNewswire

    resTORbio Appoints Lloyd Klickstein, M.D., Ph.D., as Chief Scientific Officer

    BOSTON, May 14, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced the appointment of Lloyd Klickstein, M.D., Ph.D., as Chief Scientific Officer. “We are honored to have Lloyd join the executive team at resTORbio,” said Chen Schor, Co-Founder, President and CEO of resTORbio. “Lloyd is an exceptional physician scientist with vast experience in drug discovery and clinical development across a range of aging-related indications.

  • GlobeNewswire

    resTORbio to Present RTB101 Phase 2b Clinical Trial Data at American Thoracic Society 2019 International Conference

    BOSTON, May 13, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (TORC) today announced that it will present additional results from the Phase 2b trial evaluating RTB101 (dactolisib), an oral, selective, and potent inhibitor of target of rapamycin complex 1 (TORC1), in an oral presentation entitled “Oral TORC1 Inhibitor Dactolisib Enhances Immune Function and Reduces the Incidence of Respiratory Tract Infections (RTIs) in Elderly Subjects with Asthma” during the American Thoracic Society (ATS) International Conference in Dallas, Texas from May 17-22, 2019 (abstract #A2623). “RTIs are one of the most common triggers of asthma exacerbations and are caused by many different kinds of viruses, most of which lack current treatments,” said Joan Mannick, MD, Chief Medical Officer of resTORbio.

  • GlobeNewswire

    resTORbio Announces Initiation of Phase 3 Clinical Program of RTB101 in Clinically Symptomatic Respiratory Illness

    BOSTON, May 09, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (TORC), today announced the initiation of PROTECTOR 1, the first Phase 3 trial of RTB101, an orally administered, small molecule, potent inhibitor of target of rapamycin complex 1 (TORC1). The two PROTECTOR Phase 3 trials are designed to evaluate the safety and efficacy of RTB101 for decreasing the percent of elderly subjects with clinically symptomatic respiratory illness, defined as illness associated with a respiratory tract infection (RTI) based on prespecified diagnostic criteria, with or without laboratory-confirmation of a pathogen. “The launch of our PROTECTOR Phase 3 program is an important milestone for resTORbio and for the elderly population, as RTB101 has the potential to be the first immunotherapy for reducing the incidence of illness associated with RTIs, regardless of the causative pathogen,” said Chen Schor, Co-Founder, President and CEO of resTORbio.

  • GlobeNewswire

    resTORbio to Participate at Upcoming Investor Conferences in May

    BOSTON, May 01, 2019 -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent.

  • Zacks.com featured expert Kevin Matras highlights: Walker & Dunlop, Herc, ICICI Bank, HDFC Bank and resTORbio
    Zacks

    Zacks.com featured expert Kevin Matras highlights: Walker & Dunlop, Herc, ICICI Bank, HDFC Bank and resTORbio

    Zacks.com featured expert Kevin Matras highlights: Walker & Dunlop, Herc, ICICI Bank, HDFC Bank and resTORbio

  • Buy These 5 Stocks as New Analysts Initiate Coverage
    Zacks

    Buy These 5 Stocks as New Analysts Initiate Coverage

    Higher analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

  • GlobeNewswire

    resTORbio Announces Initiation of Phase 1b/2a Trial of RTB101 in Parkinson’s Disease

    BOSTON, April 02, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases, today announced the initiation of a Phase 1b/2a trial of RTB101, its orally administered, small molecule, potent inhibitor of target of rapamycin complex 1 (TORC1) product candidate, alone or in combination with sirolimus, in Parkinson’s disease (PD). “We believe that TORC1 may be an important therapeutic target for several neurodegenerative diseases associated with aging, in which misfolded proteins aggregate and cause neuronal toxicity. As such, we are excited to initiate our first clinical trial in PD and expand our pipeline into neurodegenerative disease,” said Chen Schor, Co-Founder, President and CEO of resTORbio.

  • GlobeNewswire

    resTORbio, Inc. Announces Closing Public Offering of Common Stock

    BOSTON, March 22, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (“resTORbio” or the “Company”) (TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases, today announced the closing of its previously announced underwritten public offering of 7,200,000 shares of its common stock at a public offering price of $6.95 per share. The gross proceeds raised in the offering, before deducting underwriting discounts and commissions and offering expenses, are approximately $50.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. BofA Merrill Lynch, SVB Leerink and Guggenheim Securities acted as joint book-running managers for the offering.

  • GlobeNewswire

    resTORbio, Inc. Announces Pricing of Public Offering of Common Stock

    BOSTON, March 19, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (“resTORbio” or the “Company”) (TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases, today announced the pricing of an underwritten public offering of 7,200,000 shares of its common stock at a public offering price of $6.95 per share.

  • GlobeNewswire

    resTORbio, Inc. Announces Proposed Public Offering of Common Stock

    BOSTON, March 18, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. ("resTORbio" or the "Company") (TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases, today announced that it has commenced an underwritten public offering of $50 million of shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. BofA Merrill Lynch, SVB Leerink and Guggenheim Securities are acting as joint book-running managers for the proposed offering.

  • GlobeNewswire

    resTORbio Reports Fourth Quarter and Full Year 2018 Financial Results

    Positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA); Phase 3 program of RTB101 expected to initiate in 2Q19 Phase 1b/2a trial of RTB101 in.

  • GlobeNewswire

    resTORbio Announces Positive End-of-Phase 2 Meeting with FDA and Planned Initiation of Global Phase 3 Program for RTB101

    BOSTON, March 18, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases, today announced plans to initiate its Phase 3 program of RTB101 10 mg once daily following its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). The Phase 3 program will evaluate whether RTB101 decreases, as compared to placebo, the percentage of subjects with clinical symptoms consistent with a respiratory tract infection (RTI) with or without laboratory-confirmation of a pathogen. "Our collaborative interactions with the FDA have us on track to start our Phase 3 program and advance RTB101 towards the potential submission of a New Drug Application (NDA).

  • GlobeNewswire

    resTORbio to Present at 8th Annual SVB Leerink Global Healthcare Conference

    BOSTON, Feb. 21, 2019 -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing a new class of medicines that target the biology of aging to.

  • GlobeNewswire

    resTORbio Appoints Erkan Baloglu, Ph.D., M.B.A., as Vice President of Drug Discovery and Medicinal Chemistry

    BOSTON, Feb. 06, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (TORC), a clinical-stage biopharmaceutical company developing a new class of medicines that target the biology of aging to prevent or treat age-related diseases, today announced the appointment of Erkan Baloglu, Ph.D., M.B.A., as Vice President, Drug Discovery and Medicinal Chemistry. “We are pleased to welcome Erkan to resTORbio, as we continue to expand our team in anticipation of building out our pipeline of novel therapeutics for the treatment of aging-related diseases,” said Chen Schor, Co-Founder, President and CEO of resTORbio.